Sophia Scharl1, Tim Sprötge2, Michael Gerken2, Anton Scharl3, Atanas Ignatov4, Elisabeth C Inwald4, Olaf Ortmann4, Oliver Kölbl5, Monika Klinkhammer-Schalke2, Thomas Papathemelis3. 1. Department of Radiation Oncology and Nuclear Medicine, Medizinisches Versorgungszentrum am Klinikum Rosenheim, Rosenheim, Germany. sophiascharl@yahoo.de. 2. Tumor Center, Institute for Quality Management and Health Services Research, University of Regensburg, Regensburg, Germany. 3. Department of Gynecology and Obstetrics, Klinikum St. Marien Amberg, Amberg, Germany. 4. Department of Gynecology and Obstetrics, University Medical Center, Regensburg, Regensburg, Germany. 5. Department of Radiation Oncology, University Medical Center, Regensburg, Regensburg, Germany.
Abstract
PURPOSE: Treatment according to guidelines has been demonstrated to improve survival in a number of different cancer entities. Deviations from guidelines depend on several factors, including the patient's preferences, age and comorbidities. The aim of this study was to assess the adherence to guideline recommendations concerning surgical and adjuvant treatment in endometrial cancer. Furthermore, we sought to evaluate the reasons for non-adherence to guidelines by further examining the influence of comorbidities and age. METHODS: The influence of age, comorbidities, tumor stage and histological subtype on guideline adherence was evaluated by multivariable logistic regression in a cohort of 353 high-grade endometrial cancer patients. High-grade endometrial cancer was defined as carcinosarcoma, Type II (serous, clear cell, mixed cell carcinoma) and Type I G3 histology. RESULTS: Extensive surgical procedures, particularly systematic LNE, were less frequently applied in patients with comorbidities (p = 0.015) or higher age (p < 0.01). Guideline adherence was not affected by comorbidities (p = 0.563), but was significantly reduced with higher age (p < 0.01). In a multivariable model, higher age (p < 0.01), obesity (p = 0.011), higher FIGO Stage (p < 0.01) and histologic subtype (p < 0.01) significantly decreased OS. Surgery (p < 0.001), chemotherapy (p < 0.01) and systematic LNE (p = 0.011) were associated with higher OS. CONCLUSION: Age seems to be the strongest independent factor leading to guideline deviation. Comorbidities were associated with less aggressive treatment, but not with deviations from guidelines.
PURPOSE: Treatment according to guidelines has been demonstrated to improve survival in a number of different cancer entities. Deviations from guidelines depend on several factors, including the patient's preferences, age and comorbidities. The aim of this study was to assess the adherence to guideline recommendations concerning surgical and adjuvant treatment in endometrial cancer. Furthermore, we sought to evaluate the reasons for non-adherence to guidelines by further examining the influence of comorbidities and age. METHODS: The influence of age, comorbidities, tumor stage and histological subtype on guideline adherence was evaluated by multivariable logistic regression in a cohort of 353 high-grade endometrial cancer patients. High-grade endometrial cancer was defined as carcinosarcoma, Type II (serous, clear cell, mixed cell carcinoma) and Type I G3 histology. RESULTS: Extensive surgical procedures, particularly systematic LNE, were less frequently applied in patients with comorbidities (p = 0.015) or higher age (p < 0.01). Guideline adherence was not affected by comorbidities (p = 0.563), but was significantly reduced with higher age (p < 0.01). In a multivariable model, higher age (p < 0.01), obesity (p = 0.011), higher FIGO Stage (p < 0.01) and histologic subtype (p < 0.01) significantly decreased OS. Surgery (p < 0.001), chemotherapy (p < 0.01) and systematic LNE (p = 0.011) were associated with higher OS. CONCLUSION: Age seems to be the strongest independent factor leading to guideline deviation. Comorbidities were associated with less aggressive treatment, but not with deviations from guidelines.
Authors: Marco Johannes Battista; Marcus Schmidt; Nicole Rieks; Isabel Sicking; Stefan Albrich; Michael Eichbaum; Heinz Koelbl; Peter Mallmann; Gerald Hoffmann; Eric Steiner Journal: J Cancer Res Clin Oncol Date: 2014-09-26 Impact factor: 4.553
Authors: L Schwentner; R Wolters; K Koretz; M B Wischnewsky; R Kreienberg; R Rottscholl; A Wöckel Journal: Breast Cancer Res Treat Date: 2011-12-29 Impact factor: 4.872
Authors: Regine Wolters; Jörg Wischhusen; Tanja Stüber; Claire Rachel Weiss; Mathias Krockberger; Catharina Bartmann; Maria Blettner; Wolfgang Janni; Rolf Kreienberg; Lukas Schwentner; Igor Novopashenny; Manfred Wischnewsky; Achim Wöckel; Joachim Diessner Journal: Breast Cancer Res Treat Date: 2015-06-24 Impact factor: 4.872
Authors: Marco Johannes Battista; Marcus Schmidt; Nicole Rieks; Joscha Steetskamp; Isabel Sicking; Antje Lebrecht; Heinz Koelbl; Peter Mallmann; Gerald Hoffmann; Eric Steiner Journal: J Cancer Res Clin Oncol Date: 2014-07-02 Impact factor: 4.553
Authors: D Boll; R H A Verhoeven; M A van der Aa; M L M Lybeert; J W W Coebergh; M L G Janssen-Heijnen Journal: Eur J Cancer Date: 2011-04-27 Impact factor: 9.162
Authors: F A Eggink; C H Mom; D Boll; N P M Ezendam; R F P M Kruitwagen; J M A Pijnenborg; M A van der Aa; H W Nijman Journal: Gynecol Oncol Date: 2017-05-25 Impact factor: 5.482
Authors: L Schwentner; R Van Ewijk; C Kurzeder; I Hoffmann; J König; R Kreienberg; M Blettner; A Wöckel Journal: Eur J Cancer Date: 2012-09-06 Impact factor: 9.162